文献速递肝病

灯盏花素通过抑制TAK1依赖信号缓解NASH

Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling.
PubMed 文献 · Hepatology · 2021-12-19

该研究在体内外代谢应激模型中评估灯盏花素对NASH的作用。灯盏花素显著减轻高脂饮食、高脂高胆固醇饮食及蛋氨酸胆碱缺乏饮食小鼠的脂质蓄积、炎症、肝损伤和纤维化。机制上,灯盏花素直接结合并抑制TAK1磷酸化及其下游MAPK信号,TAK1抑制剂可消除其保护作用,提示灯盏花素可能成为NASH治疗候选药物。

要点

  • 灯盏花素在三种饮食诱导的小鼠模型中减轻肝脏脂质蓄积、炎症、损伤和纤维化。
  • 灯盏花素直接结合TAK1并抑制其磷酸化及下游MAPK信号 cascade。
  • TAK1抑制剂5Z-7-oxozeaenol可消除灯盏花素在代谢应激下的肝保护作用。

核心结论

  • 灯盏花素通过直接抑制TAK1信号阻止代谢应激诱导的NASH进展,可能成为NASH治疗候选药物。

研究设计与样本

  • 研究在体内和体外代谢应激模型中评估灯盏花素对肝脏脂肪变、炎症和纤维化的作用。
  • 体内使用高脂饮食、高脂高胆固醇饮食或蛋氨酸胆碱缺乏饮食喂养的小鼠。

主要发现

  • 灯盏花素显著减少三种饮食喂养小鼠的脂质蓄积、炎性细胞浸润、肝损伤和纤维化。
  • 灯盏花素减轻代谢应激肝细胞的脂质蓄积、炎症和脂毒性。
  • RNA测序和多组学分析提示灯盏花素抗NASH关键机制为抑制TAK1磷酸化及下游MAPK信号级联。
  • TAK1抑制剂5Z-7-oxozeaenol处理可消除灯盏花素在代谢应激下的肝保护作用。
  • 分子对接显示灯盏花素直接结合TAK1。

临床怎么用

  • 灯盏花素可能作为NASH治疗的候选药物,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is a key component of metabolic syndrome, ranging from nonalcoholic fatty liver to NASH, and is now becoming the leading cause of cirrhosis and HCC worldwide. However, due to the complex and unclear pathophysiological mechanism, there are no specific approved agents for treating NASH. Breviscapine, a natural flavonoid prescription drug isolated from the traditional Chinese herb Erigeron breviscapus, exhibits a wide range of pharmacological properties, including effects on metabolism. However, the anti-NASH efficacy and mechanisms of breviscapine have not yet been characterized. APPROACH AND RESULTS: We evaluated the effects of breviscapine on the development of hepatic steatosis, inflammation, and fibrosis in vivo and in vitro under metabolic stress. Breviscapine treatment significantly reduced lipid accumulation, inflammatory cell infiltration, liver injury, and fibrosis in mice fed a high-fat diet, a high-fat/high-cholesterol diet, or a methionine- and choline-deficient diet. In addition, breviscapine attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes undergoing metabolic stress. RNA-sequencing and multiomics analyses further indicated that the key mechanism linking the anti-NASH effects of breviscapine was inhibition of TGF-β-activated kinase 1 (TAK1) phosphorylation and the subsequent mitogen-activated protein kinase signaling cascade. Treatment with the TAK1 inhibitor 5Z-7-oxozeaenol abrogated breviscapine-mediated hepatoprotection under metabolic stress. Molecular docking illustrated that breviscapine directly bound to TAK1. CONCLUSION: Breviscapine prevents metabolic stress-induced NASH progression through direct inhibition of TAK1 signaling. Breviscapine might be a therapeutic candidate for the treatment of NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lan T, Jiang S, Zhang J, et al. Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling. Hepatology. 2021. PMID: 34717002. doi:10.1002/hep.32221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。